only. Animal Model: OVCAR3-bearing mice[1] Dosage: 15, 50, and 300 ppm (equivalent to approximately 3, 10, and 60 mg/kg/day) Administration: Oral; daily; for 21 days Result: Resulted in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth. Clinical Trial ...
50, and 300 ppm (equivalent to approximately 3, 10, and 60 mg/kg/day) Administration: Oral; daily; for 21 days Result: Resulted in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth. Clinical Trial
A Phase I clinical trial (NCT04855656- Mythic Study) is currently underway to evaluate RP-6306 in patients with advanced solid tumors.doi:10.1158/1538-7445.AM2022-5650Jimmy FourtounisJohn MartinoRino StoccoPrasamit BaruahNicole DuffyDavid Gallo...
50, and 300 ppm (equivalent to approximately 3, 10, and 60 mg/kg/day) Administration: Oral; daily; for 21 days Result: Resulted in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth. Clinical Trial
Ilioinguinal nerve excision in open mesh repair of inguinal hernia—results of a randomized clinical trial: simple solution for a difficult problem? - Scie... Inguinodynia is the second most common complication occurring after inguinal hernia repair. This study was undertaken to evaluate the effect...